FDA supports tighter restrictions on hydrocodone
WASHINGTON — The Food and Drug Administration is recommending tighter restrictions on prescription medicines containing hydrocodone, the highly addictive painkiller that has grown into the most widely prescribed drug in the United States.
In a major policy shift, the agency said in an online notice on Thursday that hydrocodone-containing drugs should be subject to the same restrictions as other narcotic drugs such as oxycodone and morphine.
More than a decade has passed since the Drug Enforcement Agency asked the FDA to reclassify hydrocodone so that it would be subject to the same restrictions as other opioid drugs. The FDA did not issue a formal announcement about its decision, which has long been sought by many patient advocates, doctors and lawmakers.
In early December, the FDA says it will formally request that hydrocodone be classified as a Schedule II drug, limiting who can write a prescription and how many times it can be refilled.
Show commenting policy
TribLive commenting policy
- Clinton: Women ‘expect’ extremism from terrorists, not GOP candidates
- People who knew Virginia TV station shooter Flanagan recall his quick temper
- Planned Parenthood alleges ‘smear’ campaign in letter to top lawmakers
- Obama marks Hurricane Katrina anniversary in New Orleans visit
- Ex-crime lab chief: Illegal’s fatal shot in San Francisco likely accidental
- Bison gores worker on California’s Catalina Island
- Compatibility of 1st-responder radios in doubt
- 13 states spared EPA regulation of waterways
- US economy surged at 3.7 percent rate in April-June quarter
- Benghazi suspect’s interrogation on 13-day ship transport to U.S. draws scrutiny
- Hawaii coral reefs under observation as dangerous bleaching expected again soon